Interventional device developer Abbott Vascular Devices, a subsidiary of Abbott Laboratories of Abbott Park, IL, reported that it has completed patient enrollment for its ZoMaxx I international drug-eluting coronary stent clinical trial.
The firm said ZoMaxx I is a 400-patient clinical trial comparing the ZoMaxx drug-eluting coronary stent to Boston Scientific's (Natick, MA) Taxus Express2 drug-eluting stent with a primary end point of nine-month in-segment late loss. Abbot said it expects to present data from the study in 2006, and that it is on track for obtaining the European CE Mark with ZoMaxx in the second half of 2006.
By AuntMinnie.com staff writers
July 22, 2005
Related Reading
Abbott debuts TriMaxx stent in Europe, May 25, 2005
Abbott submits StarClose PMA, April 13, 2005
Abbott gets FDA OK for ZoMaxx trial, April 7, 2005
Abbott to launch carotid stent trial, January 20, 2005
Abbott plans drug-eluting stent trial, September 28, 2004
Copyright © 2005 AuntMinnie.com
